1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 3
FEATURED COMPANIES
- Allergan Plc
- AstraZeneca Plc
- Celgene Corp.
- MORE
Global Mantle Cell Lymphoma Therapeutics Market: About this market
Mantle cell lymphoma therapeutics are available in combination therapy and monotherapy. The mantle cell lymphoma therapeutics market analysis considers sales from the combination therapy and monotherapy segments. Our analysis also considers the sales of mantle cell lymphoma therapeutics in Asia, Europe, North America, and ROW. In 2018, the combination therapy segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as the reduced drug resistance and rising development and commercialization of combination therapies will significantly help the market segment in maintaining its leading position. Also, our global mantle cell lymphoma therapeutics report has observed market growth factors such as recent approvals, introduction of targeted therapies, and growth of geriatric population. However, adverse effects of available therapeutics, limited access to treatment, and presence of stringent regulations may hamper the growth of the mantle cell lymphoma therapeutics industry over the forecast period.
Global Mantle Cell Lymphoma Therapeutics Market: Overview
Recent approvals
The significant unmet need for the treatment of mantle cell lymphoma has given the market vendors scope to develop reliable therapeutics. The rising formulation of therapeutics has prompted many approvals in the last few years, increasing the sales of vendors. As a result, recent approvals will lead to the expansion of the mantle cell lymphoma therapeutics market at a CAGR of over 7% during the forecast period.
Advent of novel therapies
Vendors are formulating advanced therapeutics to cater to the market demand. For instance, kinase inhibitors and gene therapies exhibit high efficacy, increasing their demand. Therefore, this trend will have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global mantle cell lymphoma therapeutics market during the forecast period 2019-2023, contact us.
Competitive Landscape
With the presence of several major players, the global mantle cell lymphoma therapeutics market is concentrated. The robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading mantle cell lymphoma therapeutics manufacturers, which include Allergan Plc, AstraZeneca Plc, Celgene Corp., Johnson & Johnson Services Inc., and Takeda Pharmaceutical Co. Ltd.
Also, the mantle cell lymphoma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Mantle cell lymphoma therapeutics are available in combination therapy and monotherapy. The mantle cell lymphoma therapeutics market analysis considers sales from the combination therapy and monotherapy segments. Our analysis also considers the sales of mantle cell lymphoma therapeutics in Asia, Europe, North America, and ROW. In 2018, the combination therapy segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as the reduced drug resistance and rising development and commercialization of combination therapies will significantly help the market segment in maintaining its leading position. Also, our global mantle cell lymphoma therapeutics report has observed market growth factors such as recent approvals, introduction of targeted therapies, and growth of geriatric population. However, adverse effects of available therapeutics, limited access to treatment, and presence of stringent regulations may hamper the growth of the mantle cell lymphoma therapeutics industry over the forecast period.
Global Mantle Cell Lymphoma Therapeutics Market: Overview
Recent approvals
The significant unmet need for the treatment of mantle cell lymphoma has given the market vendors scope to develop reliable therapeutics. The rising formulation of therapeutics has prompted many approvals in the last few years, increasing the sales of vendors. As a result, recent approvals will lead to the expansion of the mantle cell lymphoma therapeutics market at a CAGR of over 7% during the forecast period.
Advent of novel therapies
Vendors are formulating advanced therapeutics to cater to the market demand. For instance, kinase inhibitors and gene therapies exhibit high efficacy, increasing their demand. Therefore, this trend will have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global mantle cell lymphoma therapeutics market during the forecast period 2019-2023, contact us.
Competitive Landscape
With the presence of several major players, the global mantle cell lymphoma therapeutics market is concentrated. The robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading mantle cell lymphoma therapeutics manufacturers, which include Allergan Plc, AstraZeneca Plc, Celgene Corp., Johnson & Johnson Services Inc., and Takeda Pharmaceutical Co. Ltd.
Also, the mantle cell lymphoma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 3
FEATURED COMPANIES
- Allergan Plc
- AstraZeneca Plc
- Celgene Corp.
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
List of Exhibits
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Combination therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Combination therapy - Year-over-year growth 2019-2023 (%)
Exhibit 22: Monotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Monotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Proportion of geriatric population in Asia 2007 and 2017
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Pipeline molecules
Exhibit 44: Growth in geriatric population 2013-2017 (%)
Exhibit 45: Side effects of drugs treating mantle cell lymphoma
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Drug designations
Exhibit 48: Recently approved drug designations to drug candidates aimed to treat mantle cell lymphoma
Exhibit 49: Vendor landscape
Exhibit 50: Landscape disruption
Exhibit 51: Vendors covered
Exhibit 52: Vendor classification
Exhibit 53: Market positioning of vendors
Exhibit 54: Allergan Plc - Vendor overview
Exhibit 55: Allergan Plc - Business segments
Exhibit 56: Allergan Plc - Organizational developments
Exhibit 57: Allergan Plc - Geographic focus
Exhibit 58: Allergan Plc - Segment focus
Exhibit 59: Allergan Plc - Key offerings
Exhibit 60: Allergan Plc - Key customers
Exhibit 61: AstraZeneca Plc - Vendor overview
Exhibit 62: AstraZeneca Plc - Product segments
Exhibit 63: AstraZeneca Plc - Organizational developments
Exhibit 64: AstraZeneca Plc - Geographic focus
Exhibit 65: AstraZeneca Plc - Key offerings
Exhibit 66: AstraZeneca Plc - Key customers
Exhibit 67: Celgene Corp. - Vendor overview
Exhibit 68: Celgene Corp. - Business segments
Exhibit 69: Celgene Corp. - Organizational developments
Exhibit 70: Celgene Corp. - Geographic focus
Exhibit 71: Celgene Corp. - Key offerings
Exhibit 72: Celgene Corp. - Key customers
Exhibit 73: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 74: Johnson & Johnson Services, Inc. - Business segments
Exhibit 75: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 76: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 77: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 78: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 79: Johnson & Johnson Services, Inc. - Key customers
Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 82: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 83: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 84: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 85: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 86: Validation techniques employed for market sizing
Exhibit 87: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by product
- Comparison by product
- Combination therapy - Market size and forecast 2018-2023
- Monotherapy - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
- Advent of novel therapies
- Research grants and funding
- Special drug designations
- Overview
- Landscape disruption
- Competitive scenario
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Allergan Plc
- AstraZeneca Plc
- Celgene Corp.
- Johnson & Johnson Services Inc.
- Takeda Pharmaceutical Co. Ltd.
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Combination therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Combination therapy - Year-over-year growth 2019-2023 (%)
Exhibit 22: Monotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Monotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Proportion of geriatric population in Asia 2007 and 2017
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Pipeline molecules
Exhibit 44: Growth in geriatric population 2013-2017 (%)
Exhibit 45: Side effects of drugs treating mantle cell lymphoma
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Drug designations
Exhibit 48: Recently approved drug designations to drug candidates aimed to treat mantle cell lymphoma
Exhibit 49: Vendor landscape
Exhibit 50: Landscape disruption
Exhibit 51: Vendors covered
Exhibit 52: Vendor classification
Exhibit 53: Market positioning of vendors
Exhibit 54: Allergan Plc - Vendor overview
Exhibit 55: Allergan Plc - Business segments
Exhibit 56: Allergan Plc - Organizational developments
Exhibit 57: Allergan Plc - Geographic focus
Exhibit 58: Allergan Plc - Segment focus
Exhibit 59: Allergan Plc - Key offerings
Exhibit 60: Allergan Plc - Key customers
Exhibit 61: AstraZeneca Plc - Vendor overview
Exhibit 62: AstraZeneca Plc - Product segments
Exhibit 63: AstraZeneca Plc - Organizational developments
Exhibit 64: AstraZeneca Plc - Geographic focus
Exhibit 65: AstraZeneca Plc - Key offerings
Exhibit 66: AstraZeneca Plc - Key customers
Exhibit 67: Celgene Corp. - Vendor overview
Exhibit 68: Celgene Corp. - Business segments
Exhibit 69: Celgene Corp. - Organizational developments
Exhibit 70: Celgene Corp. - Geographic focus
Exhibit 71: Celgene Corp. - Key offerings
Exhibit 72: Celgene Corp. - Key customers
Exhibit 73: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 74: Johnson & Johnson Services, Inc. - Business segments
Exhibit 75: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 76: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 77: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 78: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 79: Johnson & Johnson Services, Inc. - Key customers
Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 82: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 83: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 84: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 85: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 86: Validation techniques employed for market sizing
Exhibit 87: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 3
LOADING...
4 of 3
- Allergan Plc
- AstraZeneca Plc
- Celgene Corp.
- Johnson & Johnson Services Inc.
- Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
